

18. Khafagy el, S.; Morishita, M.; Isowa, K.; Imai, J.; Takayama, K. Effect of Cell-Penetrating Peptides on the Nasal Absorption of Insulin. *J. Controlled Release* **2009**, *133*, 103–108.
19. Zhu, X.; Shan, W.; Zhang, P.; Jin, Y.; Guan, S.; Fan, T.; Yang, Y.; Zhou, Z.; Huang, Y. Penetratin Derivative-Based Nanocomplexes for Enhanced Intestinal Insulin Delivery. *Mol. Pharmaceutics* **2014**, *11*, 317–328.
20. Madani, F.; Lindberg, S.; Langel, U.; Futaki, S.; Graslund, A. Mechanisms of Cellular Uptake of Cell-Penetrating Peptides. *J. Biophys.* **2011**, *2011*, 414729.
21. Duncan, R.; Vicent, M. J. Do HPMA Copolymer Conjugates Have a Future as Clinically Useful Nanomedicines? A Critical Overview of Current Status and Future Opportunities. *Adv. Drug Delivery Rev.* **2010**, *62*, 272–282.
22. Kopeček, J.; Kopecková, P. HPMA Copolymers: Origins, Early Developments, Present, and Future. *Adv. Drug Delivery Rev.* **2010**, *62*, 122–149.
23. Ulbrich, K.; Subr, V. Structural and Chemical Aspects of HPMA Copolymers as Drug Carriers. *Adv. Drug Delivery Rev.* **2010**, *62*, 150–166.
24. Etrych, T.; Jelinková, M.; Rihová, B.; Ulbrich, K. New HPMA Copolymers Containing Doxorubicin Bound via pH-Sensitive Linkage: Synthesis and Preliminary *in Vitro* and *in Vivo* Biological Properties. *J. Controlled Release* **2001**, *73*, 89–102.
25. Bissett, D.; Cassidy, J.; de Bono, J. S.; Muirhead, F.; Main, M.; Robson, L.; Fraier, D.; Magne, M. L.; Pellizzoni, C.; Porro, M. G.; et al. Phase I and Pharmacokinetic (PK) Study of MAG-CPT (PNU 166148): A Polymeric Derivative of Camptothecin (CPT). *Br. J. Cancer* **2004**, *91*, 50–55.
26. Seymour, L. W.; Ferry, D. R.; Kerr, D. J.; Rea, D.; Whitlock, M.; Poyner, R.; Boivin, C.; Hesslewood, S.; Twelves, C.; Blackie, R.; et al. Phase II Studies of Polymer-Doxorubicin (PK1, FCE28068) in the Treatment of Breast, Lung and Colorectal Cancer. *Int. J. Oncol.* **2009**, *34*, 1629–1636.
27. Lakowicz, J. R.; Masters, B. R. Principles of Fluorescence Spectroscopy. *J. Biomed. Opt.* **2008**, *13*, 9901.
28. Tang, B. C.; Dawson, M.; Lai, S. K.; Wang, Y. Y.; Suk, J. S.; Yang, M.; Zeitlin, P.; Boyle, M. P.; Fu, J.; Hanes, J. Biodegradable Polymer Nanoparticles That Rapidly Penetrate the Human Mucus Barrier. *Proc. Natl. Acad. Sci. U. S. A.* **2009**, *106*, 19268–19273.
29. Schuster, B. S.; Suk, J. S.; Woodworth, G. F.; Hanes, J. Nanoparticle Diffusion in Respiratory Mucus from Humans without Lung Disease. *Biomaterials* **2013**, *34*, 3439–3446.
30. Lai, S. K.; O'Hanlon, D. E.; Harrold, S.; Man, S. T.; Wang, Y. Y.; Cone, R.; Hanes, J. Rapid Transport of Large Polymeric Nanoparticles in Fresh Undiluted Human Mucus. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 1482–1487.
31. Behrens, I.; Stenberg, P.; Artursson, P.; Kissel, T. Transport of Lipophilic Drug Molecules in a New Mucus-Secreting Cell Culture Model Based on HT29-MTX Cells. *Pharm. Res.* **2001**, *18*, 1138–1145.
32. Behrens, I.; Pena, A. I.; Alonso, M. J.; Kissel, T. Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport. *Pharm. Res.* **2002**, *19*, 1185–1193.
33. Burd, C. G. Physiology and Pathology of Endosome-to-Golgi Retrograde Sorting. *Traffic* **2011**, *12*, 948–955.
34. Yanes, R. E.; Tarn, D.; Hwang, A. A.; Ferris, D. P.; Sherman, S. P.; Thomas, C. R.; Lu, J.; Pyle, A. D.; Zink, J. I.; Tamanoi, F. Involvement of Lysosomal Exocytosis in the Excretion of Mesoporous Silica Nanoparticles and Enhancement of the Drug Delivery Effect by Exocytosis Inhibition. *Small* **2013**, *9*, 697–704.
35. Yang, M.; Lai, S. K.; Yu, T.; Wang, Y. Y.; Happe, C.; Zhong, W.; Zhang, M.; Anonuevo, A.; Fridley, C.; Hung, A.; et al. Nanoparticle Penetration of Human Cervicovaginal Mucus: The Effect of Polyvinyl Alcohol. *J. Controlled Release* **2014**, *192*, 202–208.
36. Ulbrich, K.; Subr, V.; Strohalm, J.; Plocová, D.; Jelinková, M.; Rihová, B. Polymeric Drugs Based on Conjugates of Synthetic and Natural Macromolecules. I. Synthesis and Physico-Chemical Characterisation. *J. Controlled Release* **2000**, *64*, 63–79.
37. Duncan, R.; Cable, H. C.; Lloyd, J. B.; Rejmanová, P.; Kopeček, J. Polymers Containing Enzymatically Degradable Bonds. 7. Design of Oligopeptide Side-Chains in Poly[N-(2-hydroxypropyl)methacrylamide] Copolymers to Promote Efficient Degradation by Lysosomal Enzymes. *Macromol. Chem. Phys.* **1983**, *184*, 1997–2008.
38. Due, C.; Linnert, K.; Langeland Johansen, N.; Olsson, L. Analysis of Insulin Receptors on Heterogeneous Eukaryotic Cell Populations with Fluorochrome-Conjugated Insulin and Fluorescence-Activated Cell Sorter. Advantages and Limitations to the ¹²⁵I-Labelled Insulin Methodology. *Diabetologia* **1985**, *28*, 749–755.
39. Tanaka, S.; Podolsky, D. K.; Engel, E.; Guth, P. H.; Kaunitz, J. D. Human Spasmolytic Polypeptide Decreases Proton Permeation through Gastric Mucus *in Vivo* and *in Vitro*. *Am. J. Physiol.* **1997**, *272*, G1473–1480.
40. Bae, H. D.; Lee, K. On Employing a Translationally Controlled Tumor Protein-Derived Protein Transduction Domain Analog for Transmucosal Delivery of Drugs. *J. Controlled Release* **2013**, *170*, 358–364.
41. He, B.; Lin, P.; Jia, Z.; Du, W.; Qu, W.; Yuan, L.; Dai, W.; Zhang, H.; Wang, X.; Wang, J.; et al. The Transport Mechanisms of Polymer Nanoparticles in Caco-2 Epithelial Cells. *Biomaterials* **2013**, *34*, 6082–6098.
42. Sarmiento, B.; Martins, S.; Ferreira, D.; Souto, E. B. Oral Insulin Delivery by Means of Solid Lipid Nanoparticles. *Int. J. Nanomed.* **2007**, *2*, 743–749.